Background: Cancer immunotherapy is one of the most promising research areas in the field of cancer therapy. Many pharmaceutical and biotech companies in the world are devoting great effort to develop cancer immunity-related treatment antibodies. However, along the IO drug development process, in vivo efficacy models have always been a rate-limiting step. Methods: In most cases, a human monoclonal antibody does not have mouse crossreactivity. Mouse surrogate antibodies were often used in immune-competent syngeneic mouse models to evaluate in vivo efficacy of IO drugs. However, the efficacy of a surrogate antibody cannot fully represent the human drug in the clinical scenario. Therefore, we generated humanized knock-in mice to evaluate the in vivo efficacy of human IO antibodies.
Results: For example, human 4-1BB knock-in (B-h4-1BB) mice were generated with a chimeric 4-1BB receptor, which is recognizable by stimulatory human 4-1BB antibodies. Additionally, more knock-in mice targeting stimulatory immune checkpoint molecules were developed and validated, such as B-hCD3e, B-hCD40, B-hOX40, B-hGITR, B-hCD27, B-hCD28 et al.
Conclusions:
All these mouse models response well to the corresponding human IO antibodies, proving that they are powerful tools for in vivo efficacy evaluation of human stimulatory immune checkpoint antibodies. Legal entity responsible for the study: Beijing Biocytogen Co., Ltd. Methods: Inclusion of the PI-3K inhibitor LY294002 into the manufacturing process was the first strategy used as an initial effort focused upon blunting the activity of the CAR T cells. We subsequently developed a process that included a NKG2D blocking antibody during the expansion phase of cell culture.
Results: LY294002 was shown to reversibly reduce NKG2D expression at the cell surface. Consequently, this inhibitor partially controlled fratricide during manufacturing and enhanced viability post-thawing which enabled the initiation of the THINK (NCT03018405) clinical trial. As the trial moved through the dose-escalation phase towards the upper dose level (production of more than 10 10 cells), there was an increase in the level of manufacturing failures. This was largely linked to the effect of LY294002 upon T cell proliferation and the challenge faced manufacturing CAR T cells from patients with advanced cancer. Therefore, we subsequently developed a process that included a NKG2D blocking antibody during the expansion phase of cell culture. This strategy enabled the expansion of CYAD-01 T cells to the levels required for the THINK clinical trial. After fine tuning the process, the CYAD-01 CAR T cells generated showed high comparability to the CYAD-01 CAR T cells produced in the first part of the trial. This process has been in place for the THINK trial since January 2018. Conclusions: Together, these results indicate that when fratricide is an issue preventing clinical development, CAR T cells can be efficiently manufactured through PI-3K inhibition and antibody mediated receptor blockade. Legal entity responsible for the study: Celyad SA. Background: The NKG2D receptor is a type II transmembrane glycoprotein playing an important role in anti-tumor responses. In humans, NKG2D binds to eight ligands, MHC class I-related chain MICA and B and unique long 16 (UL16)-binding proteins ULBP 1-6. The surface expression of NKG2D ligands (NKG2DL) is highly regulated to avoid inappropriate immune responses in physiological conditions but is induced by various stress situations such as malignant transformation or inflammation. NKG2DL expression on tumors has been reported in the literature. However, a systematic study on all NKG2DL in a large array of normal tissues and tumor samples is lacking. Celyad is pursuing the clinical development of NKG2D based chimeric antigen receptor (CAR) T cell therapy and robust data are thus required to adequately support this work. Methods: We performed an extensive immunohistochemistry study on primary tumors and normal adjacent tissues from patients suffering from pancreatic, breast, ovarian, bladder, colorectal and lung carcinomas and on a series of normal tissues from non-cancer patients. Results: MICA/B were the most frequently and highly expressed. Interestingly the subset of triple negative breast cancers (TNBC) showed strong membranous staining for all NKG2DL on tumor cells making this patient subpopulation a very attractive therapeutic target for NKG2D-based therapies. There was no clear correlation between the expression of NKG2DL and the clinical stage of the tumors indicating that every stage of the diseases could be targeted. In bladder, TNBC, CRC and pancreatic tumors, tumor cells were frequently stained for multiple NKG2DL implying that these tumors would not be susceptible to immune escape. Tumor-associated fibrovascular structures displayed generally membranous staining within the endothelial compartment suggesting that NKG2D-based CAR T therapy can target simultaneously both the tumor and the tumor microenvironment. Conclusions: In conclusion, this extensive immunohistochemistry study supports the concept of targeting NKG2DL for cancer therapy. Legal entity responsible for the study: Celyad SA. 
